Woodline Partners LP Kinnate Biopharma Inc. Transaction History

Woodline Partners LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$3.46 - $7.98 $3.12 Million - $7.2 Million	902,196 Added 481.43%	1,089,594 $6.81 Million
Q4 2022 Feb 14, 2023	SELL	$5.26 - $12.19 $1.77 Million - $4.11 Million	-337,271 Reduced 64.28%	187,398 $1.14 Million
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $2.61 Million - $4.17 Million	264,393 Added 101.58%	524,669 $6.27 Million
Q2 2021 Aug 16, 2021	SELL	$22.19 - $31.55 $573,678 - $815,662	-25,853 Reduced 9.04%	260,276 $6.06 Million
Q1 2021 May 17, 2021	BUY	$26.99 - $40.0 $261,209 - $387,120	9,678 Added 3.5%	286,129 $8.92 Million

Q4 2020 Feb 16, 2021	BUY	$36.35 - $45.25 $10 Million - $12.5 Million	276,451 New	276,451 $11 Million

32.9M

94.7K

802K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.